Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Paying $1.53bn Upfront For Zuranolone And SAGE-324
Executive Summary
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
You may also be interested in...
After CRL In MDD, Sage/Biogen’s Zuranolone Would Need More Effectiveness Data
Zurzuvae becomes first oral drug for postpartum depression but will need at least one additional study to enter larger major depressive disorder market after US FDA cites a lack of effectiveness. Continued MDD development in doubt with both Sage and partner Biogen in cost-cutting frame.
Reprioritization On Cards After Sage/Biogen’s Zurzuvae Receives CRL For MDD
The firms’ Zurzuvae has become the first oral drug to win US approval for postpartum depression but a thumbs down in the larger major depressive disorder indication has raised concerns that Biogen could pull out of the partnership as Sage turns its efforts to cutting costs.
Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.